Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X. Rugo HS, et al. Among authors: aldrighetti d. Breast Cancer Res Treat. 2013 Jun;139(2):411-9. doi: 10.1007/s10549-013-2552-8. Epub 2013 May 7. Breast Cancer Res Treat. 2013. PMID: 23649189 Free PMC article. Clinical Trial.
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
Baldini E, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Carnino F, Gallo L, Giannessi P, Conte PF, Orlandini C, Bruzzi P. Baldini E, et al. Among authors: aldrighetti d. Br J Cancer. 2004 Jul 5;91(1):45-9. doi: 10.1038/sj.bjc.6601883. Br J Cancer. 2004. PMID: 15173858 Free PMC article. Clinical Trial.
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Mammoliti S, Carnino F, Giannessi P, Costantini M, Moyano A, Baldini E; Gruppo Oncologico Nord Ovest. Conte PF, et al. Among authors: aldrighetti d. Cancer. 2004 Aug 15;101(4):704-12. doi: 10.1002/cncr.20400. Cancer. 2004. PMID: 15305399 Free article. Clinical Trial.
Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, Giai M, Genta F, Pacini P, Distante V, Bolognesi A, Aldrighetti D, Farris A. Boccardo F, et al. Among authors: aldrighetti d. J Clin Oncol. 2000 Jul;18(14):2718-27. doi: 10.1200/JCO.2000.18.14.2718. J Clin Oncol. 2000. PMID: 10894871 Clinical Trial.
Antiangiogenic strategies in breast cancer management.
Giovannini M, Aldrighetti D, Zucchinelli P, Belli C, Villa E. Giovannini M, et al. Among authors: aldrighetti d. Crit Rev Oncol Hematol. 2010 Oct;76(1):13-35. doi: 10.1016/j.critrevonc.2009.12.004. Epub 2010 Aug 11. Crit Rev Oncol Hematol. 2010. PMID: 20702105 Review.
Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.
Viale G, Licata L, Sica L, Zambelli S, Zucchinelli P, Rognone A, Aldrighetti D, Di Micco R, Zuber V, Pasetti M, Di Muzio N, Rodighiero M, Panizza P, Sassi I, Petrella G, Cascinu S, Gentilini OD, Bianchini G. Viale G, et al. Among authors: aldrighetti d. Oncologist. 2020 Jul;25(7):e1013-e1020. doi: 10.1634/theoncologist.2020-0316. Epub 2020 May 26. Oncologist. 2020. PMID: 32412693 Free PMC article.
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.
Notini G, Naldini MM, Sica L, Viale G, Rognone A, Zambelli S, Zucchinelli P, Piras M, Bosi C, Mariani M, Aldrighetti D, Bianchini G, Licata L. Notini G, et al. Among authors: aldrighetti d. Front Oncol. 2024 Mar 11;14:1374547. doi: 10.3389/fonc.2024.1374547. eCollection 2024. Front Oncol. 2024. PMID: 38529378 Free PMC article.